scholarly journals Concomittant use of Sapien 3 Transcatheter Valve for Severe MAC with Intuity Elite Rapid Deployment Valve for Aortic Stenosis

2021 ◽  
Author(s):  
Gareth J. Hooks ◽  
Peter Ball ◽  
Mark S. Spence ◽  
Reuben Jeganathan
Keyword(s):  
Mitral Valve ◽  
Aortic Stenosis ◽  
High Risk Patient ◽  
Therapeutic Benefit ◽  
Valve Prosthesis ◽  
Excellent Outcome ◽  
Sapien 3 ◽  
Transcatheter Valve ◽  
Valve Pathology ◽  
Rapid Deployment

Abstract Background-Concomitant double valve pathology in the presence of severe MAC poses significant technical challenges when planning surgical intervention. With continued evolution of valve prosthesis, innovative techniques can be considered with the potential for additional therapeutic benefit. Case presentation-We present a novel technique of using a rapid deployment surgical aortic valve in combination with open surgical transcatheter mitral valve implantation (TMVI) for severe Mitral Annular Calcification (MAC). The Intuity Elite rapid deployment prosthesis (Edwards Lifesciences, Irvine, CA) was used concomitantly with the Sapien 3 (Edwards Lifesciences, Irvine, CA) transcatheter prosthesis trans-atrially on cardiopulmonary bypass in a patient with critical aortic stenosis and moderate-severe mixed mitral valve disease in the setting of severe MAC (off-label use). Conclusions-We demonstrate how both technologies can, not only be accommodated, but indeed complement each other achieving an excellent outcome in a high-risk patient.

scholarly journals Effect of SAPIEN 3 Transcatheter Valve Implantation on Health Status in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk

2018 ◽  
Vol 11 (12) ◽  
pp. 1188-1198 ◽  
Author(s):  
Suzanne J. Baron ◽  
Vinod H. Thourani ◽  
Susheel Kodali ◽  
Suzanne V. Arnold ◽  
Kaijun Wang ◽  
...  
Keyword(s):  
Health Status ◽  
Aortic Stenosis ◽  
Severe Aortic Stenosis ◽  
Surgical Risk ◽  
Sapien 3 ◽  
Transcatheter Valve ◽  
Valve Implantation

scholarly journals Mitral Valve Replacement With Sapien 3 Transcatheter Valve in Severe Mitral Annular Calcification

2017 ◽  
Vol 103 (1) ◽  
pp. e57-e59 ◽  
Author(s):  
Marek Polomsky ◽  
Konstantinos P. Koulogiannis ◽  
Robert M. Kipperman ◽  
Barry M. Cohen ◽  
Christopher J. Magovern ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Mitral Annular Calcification ◽  
Sapien 3 ◽  
Transcatheter Valve ◽  
Annular Calcification

Mitral valve-in-valve implantation during pregnancy

2021 ◽  
Vol 14 (11) ◽  
pp. e244270
Author(s):  
Mark Zachary Johnson ◽  
Nicholas James Damianopoulos ◽  
Felicity Lee ◽  
Gerald Yong
Keyword(s):  
Mitral Valve ◽  
African Woman ◽  
Valve Prosthesis ◽  
Mitral Valve Prosthesis ◽  
Valve In Valve ◽  
Transcatheter Valve ◽  
Valve Implantation ◽  
Consensus Decision ◽  
Rheumatic Heart ◽  
Mitral Bioprosthesis

A 32-year-old, 11-week pregnant African woman with known rheumatic heart disease presented to the emergency department with worsening shortness of breath on exertion. She had undergone a double bioprosthetic valve replacement and left atrial appendage resection 8 years prior for severe mitral stenosis, moderate mitral regurgitation and moderate aortic regurgitation. A transo-oesophageal echocardiography at this presentation confirmed a morphologically calcified and stenosed mitral bioprosthesis, with moderate stenosis of her aortic bioprosthesis. Her multidisciplinary team, including cardiologists, cardiothoracic surgeons and obstetricians, came to a consensus decision to proceed with a transseptal transcatheter valve implantation within the mitral valve prosthesis (valve-in-valve implantation). Transthoracic echocardiography performed 2 months post procedure showed satisfactory mitral valve gradients and at 30 weeks’ gestation, she successfully delivered her fifth child. 2 years later, the valve in valve complex is still functioning well.

P1431Radiofrequency ablation of left atrium in patients with mitral valve replacement. The future of surgical treatment for atrial fibrillation in mitral valve disease?

EP Europace ◽  
2020 ◽  
Vol 22 (Supplement_1) ◽  
Author(s):  
A Utyasheva ◽  
I V Abdulyanov ◽  
M A Sungatullin ◽  
I I Vagizov
Keyword(s):  
Atrial Fibrillation ◽  
Surgical Treatment ◽  
Mitral Valve ◽  
Sinus Rhythm ◽  
Left Atrium ◽  
Pulmonary Veins ◽  
Pacemaker Implantation ◽  
Valve Prosthesis ◽  
Diagnostic Center ◽  
Valve Pathology

Abstract Aims   The evaluation of sinus rhythm preservation after surgical treatment of atrial fibrillation by left-atrial RFA in patients with mitral valve prosthetics. Materials and methods  A prospective, randomized study was performed in the interregional clinical and diagnostic center of Kazan in 2011-2018 which were included 136 patients with mitral valve pathology and persistent AF. The average age of patients was 57 ± 5, the gender division was dominated by female patients  and made up 97 (58.4%). All patients underwent either mitral valve prosthesis with mechanical prosthesis Meding-2 which made up 96 (70.5%) or biological prosthesis Carpantier-Edwards which made up 40 (29.4%). Radiofrequency isolation of the left atrium and pulmonary veins was performed by standard procedure by Cox-IV which doesn’t include the right atrium tissue. Results and discussion: In the early post surgical period, recovery of sinus rhythm was observed in 111 (81.6%) patients. Cardiac Pacemaker Implantation was performed in 1 (0.73%) case.  The results of the study were assessed after surgical treatment in 22 ± 5 months, the sinus rhythm was preserved in 99 patients from the study group and made up 72.7%. Conclusion Radiofrequency ablation  the left atrium provides long-term preservation of sinus rhythm in the treatment of patients with atrial fibrillation and mitral valve pathology.

scholarly journals Transcatheter Mitral Valve Replacement with the Edwards Sapien 3 Valve

2017 ◽  
Vol 44 (4) ◽  
pp. 269-273 ◽  
Author(s):  
Biswajit Kar ◽  
Angelo Nascimbene ◽  
Igor D. Gregoric ◽  
Manish Patel ◽  
Pranav Loyalka
Keyword(s):  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Mitral Valve Stenosis ◽  
Transcatheter Mitral Valve Replacement ◽  
Edwards Sapien ◽  
Sapien 3 ◽  
Transcatheter Valve ◽  
Valve Implantation ◽  
Surgical Valve Replacement

We describe the case of a 57-year-old man who had severe mitral valve stenosis and regurgitation without significant annular calcification. He was not a candidate for surgical valve replacement or repair because of his substantial comorbid conditions, overall frailty, and elevated surgical risk. He underwent successful transcatheter mitral valve replacement of his native mitral valve with compassionate, off-label use of an Edwards Sapien 3 valve. A search of the literature produced no other cases like ours, which represents a further evolution of the transcatheter valve implantation concept. Further studies are needed to help define accurate valve sizing, intraprocedural positioning, and long-term device stability, as well as to determine which patients might benefit from this commercially available valve. In the meantime, our findings could present a means of treating patients who have no other options.

scholarly journals The Distinguish Method of Severe Aortic Stenosis Treatment Geriatric High Mortality Risk Patients

Kardiologiia ◽  
2020 ◽  
Vol 60 (4) ◽  
pp. 43-47
Author(s):  
E. V. Kryukov ◽  
D. L. Kranin ◽  
A. V. Gajdukov ◽  
A. Yu. Fedorov ◽  
D. A. Nazarov ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Stenosis ◽  
Severe Aortic Stenosis ◽  
Postoperative Mortality ◽  
Surgical Care ◽  
Valve Prosthesis ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Prosthesis ◽  
Risk Patients ◽  
Valve Pathology

Aim To improve quality of treatment for senile patients with pronounced aortic stenosis (AS).Material and methods Aortic valve stenosis (AS) is the most common valve pathology in cardiosurgical patients. Surgical correction of aortic valve (AV) stenosis accounts for 10 to 22 % of open-heart operations. 125 patients with pronounced AS were treated in the N. N. Burdenko Main Military Clinical Hospital between 2010 and 2017. This study was based on the implementation of new, minimally invasive methods in our clinic in 2013: balloon aortic valvuloplasty (BAVP) of the aortic valve and transcatheter aortic valve prosthesis (TCAVP).Results In the group of patients receiving the drug therapy alone, the in-hospital mortality was 2 %. At the time of maximum follow-up duration (3 years), the survival rate was 50.5 %. In the group of patients who underwent the AV replacement with extracorporeal circulation, the 3 year postoperative mortality was 16.6 %. There was no 3 year mortality in the group of patients who underwent TCAVP. The short-term beneficial effect of BAVP was confirmed.Conclusion An algorithm was developed for medical care of patients older than 75 with pronounced AS; the place of BAVP in the step-by-step management of these patients was determined. Using the developed approach in the management of these patients provided a 32 % (p<0.05) increase in the number of cases of radical surgical care.

scholarly journals Transfemoral aortic valve implantation in severe aortic stenosis patients with prior mitral valve prosthesis

2015 ◽  
Vol 4 ◽  
pp. 304-311 ◽  
Author(s):  
Cenk Sari ◽  
Serdal Baştuğ ◽  
Hüseyin Ayhan ◽  
Hacı Ahmet Kasapkara ◽  
Tahir Durmaz ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Aortic Valve ◽  
Aortic Stenosis ◽  
Severe Aortic Stenosis ◽  
Valve Prosthesis ◽  
Mitral Valve Prosthesis ◽  
Aortic Valve Implantation ◽  
Valve Implantation

scholarly journals Transseptal transcatheter valve-in-valve implantation for failed surgical mitral bioprosthesis: the first clinical experience

2020 ◽  
Vol 24 (1) ◽  
pp. 94
Author(s):  
V. I. Ganyukov ◽  
E. A. Shloido ◽  
R. S. Tarasov ◽  
N. V. Rogulina ◽  
I. K. Khalivopulo ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Aortic Valve ◽  
Conflict Of Interest ◽  
Clinical Status ◽  
Clinical Aspects ◽  
Valve Prosthesis ◽  
Transcatheter Aortic Valve ◽  
Mitral Valve Prosthesis ◽  
Transcatheter Valve ◽  
Valve Implantation

<p>A clinical case of endovascular correction of a biological mitral valve prosthesis dysfunction by implantation of a transcatheter aortic valve into the mitral position is described. Considering the clinical status of the patient, the condition was determined to be inoperable. Subsequently, based on vital fluoroscopy and echocardiography findings, the patient was implanted with a transcatheter aortic valve in the mitral valve bioprosthesis position. The technical and clinical aspects of the intervention and its results were analysed during the hospital period and for 5 months after implantation. The selected method of treatment was found to be appropriate.</p><p>Received 10 January 2020. Revised 18 March 2020. Accepted 19 March 2020.</p><p><strong>Funding</strong>: The study did not have sponsorship.</p><p><strong>Conflict of interest:</strong> Authors declare no conflict of interest.</p><p><strong>Author contributions</strong><br />Drafting the article: N.V. Rogulina, I.V. Ganyukov, A.M. Kochergina, V.I. Ganyukov, R.S. Tarasov, I.K. Khalivopulo, I.N. Sizova <br />Literature review: V.I. Ganyukov, R.S. Tarasov, N.V. Rogulina, I.K. Khalivopulo, I.V. Ganyukov, A.M. Kochergina <br />Illustrations: I.V. Ganyukov, I.N. Sizova, N.V. Rogulina <br />Critical revision of the article: V.I. Ganyukov, R.S. Tarasov, E.A. Shloido, L.S. Barbarash <br />Surgical treatment: E.A. Shloido, V.I. Ganyukov, R.S. Tarasov<br />Final approval of the version to be published: V.I. Ganyukov, E.A. Shloido, R.S. Tarasov, N.V. Rogulina, I.K. Khalivopulo, I.V. Ganyukov, A.M. Kochergina, I.N. Sizova, L.S. Barbarash</p>

Sign in / Sign up

Export Citation Format

Share Document